Temasek-backed Transcenta mulls HK-China dual IPO listing
After announcing a $100 million Series B+ funding, the biotech company’s CEO tells FinanceAsia it is now in full IPO preparation mode with Hong Kong as its preferred destination. However, a dual listing is not out of the question.
January 12, 2020
